CD24 can be found on most B lymphocytes as well as on differentiating neuroblasts and granulocytes. It is frequently associated with breast cancer, and has been found to be highly expressed in ovarian cancer. CD24 has also been found to be expressed on disseminated tumor cells, making it a potential target for therapeutics to combat metastasis.
Anti-CD24-SAP eliminates cells expressing human CD24.
The following control is recommended for validating the specificity of the beta conjugate: BIgG-SAP mouse (Cat. #IT-74).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.